Cancer Weekly articles from March 1991

Cancer Weekly archives from March 1991

G-CSF approved to protect cancer chemotherapy patients. (granulocyte colony-stimulating factor) (U.S. Food and Drug Administration)
March 4, 1991... U.S. FDA The U.S. Food and Drug Administration (FDA) announced approval of a new genetically engineered drug that can reduce the number of infections in cancer patients who may be at high risk during chemotherapy. The drug,...

Two studies suggest no role for concurrent chemotherapy in NSCLC. (non-small-cell lung cancer) (Lung Cancer Study Group/University of Cincinnati)
March 4, 1991... Lung Cancer Study Group/University of Cincinnati Two recently published studies conclude that chemotherapy given concurrently with radiotherapy offers no survival advantage in patients with non-small-cell lung cancer (NSCLC). A...

Physicians urged to enroll patients in trials. (cancer patients in clinical trials) (American Medical Association)
March 4, 1991... American Medical Association Only a small fraction of eligible patients are being accrued into clinical trials and cancer research is threatened as a result, according to a report by the American Medical Association (AMA) Council on...

Elderly receive less complete cancer therapy. (women over 65) (American Association for the Advancement of Science)
March 4, 1991... Women over age 65 with cancer are less likely to receive standard therapy than younger women with similar diagnosis, according to a University of Wisconsin Clinical Cancer Center (UWCCC) study. "Age, and not the nature of disease, appears...

Report says fluoridation presents no cancer risk. (U.S. Public Health Service)
March 4, 1991... A committee of scientific experts convened by the U.S. Public Health Service has concluded, after nine months of investigation, that water fluoridation presents no cancer risk and is safe and effective in preventing dental decay. The...

OncoScint product development update. (colorectal cancer imaging agent) (Cytogen)
March 4, 1991... Cytogen Corp. announced that it has been advised by its European marketing partner, EuroCetus, that the process to register its colorectal cancer imaging agent, OncoScint CR103, for sale in Europe continues as planned. At recently held...

Photofrin cancer treatment agreement amended with American Cyanamid. (drug) (Quadra Logic Technologies Inc.)
March 4, 1991... Quadra Logic Technologies Inc. (QLT) announced that it has finalized an amendment to the co-development and distribution agreement with American Cyanamid Company (Cyanamid). Under the terms of the amendment, QLT and Cyanamid will share...

Interferon alpha-2B approved for non-A, non-B hepatitis. (U.S. Food and Drug Administration)
March 4, 1991... The U.S. Food and Drug Administration approved injections of recombinant interferon alpha to treat chronic Non-A, Non-B hepatitis - also called hepatitis C - an infectious liver disease for which there is currently no effective treatment. ...

Breast cancer research funding needs cited. (Fox Chase Cancer Center)
March 4, 1991... Basic research is the key to significant advances in breast cancer and other major cancers, according to Dr. Robert C. Young, president of Fox Chase Cancer Center in Philadelphia, at a special legislative briefing hosted by U.S. Rep. Mary...

InterPharm Laboratories reports 1990 results. (sales) (Israel)
March 4, 1991... InterPharm Laboratories Limited reported sales of US $25.2 million for the year ending December 31, 1990, compared with $13.8 million last year, an increase of 83 percent. The increase in sales was mainly due to strong market penetration...

Key carbohydrate technology licensed from Brigham and Women's Hospital. (therapies for infectious diseases and immune system disorders) (Alpha-Beta Technology)
March 4, 1991... Alpha-Beta Technology, Inc. announced that the company has acquired from Brigham and Women's Hospital (Boston) exclusive rights to patented technology for developing an important class of carbohydrate-based therapeutics to treat infectious...

New surgical attack on colon and rectal cancer. (monoclonal antibodies) (U.S. Food and Drug Administration)
March 4, 1991... High-tech monoclonal antibodies for use in surgery against colon and rectal cancer are now undergoing U.S. Food and Drug Administration (FDA) Phase III clinical trials at 15 medical centers across the United States, including Swedish Hospital...

Cancer feared more than heart disease. (Seattle)
March 4, 1991... Seattle, Washington, residents feel very much in control of their cardiovascular destiny and fear cancer more than they do heart disease. The poll of 250 Seattle residents over 30 years of age was supported by an educational grant from...

Cancer information line expands services, hours. (Pittsburgh Cancer Institute)
March 4, 1991... The Pittsburgh Cancer Institute's toll-free Cancer Information and Referral Service (CIRS) has expanded its hours and services. According to Karen Robinson, R.N., M.N., clinical director of the CIRS, "Due to a marked increase in use of...

Food processors back decision to ignore some pesticide risks. (National Food Processors Association) (U.S. Environmental Protection Agency)
March 4, 1991... The National Food Processors Association (NFPA), representing most of the nation's packaged food manufacturers, praised a decision by the U.S. Environmental Protection Agency (EPA) to ignore trivial risks in regulating pesticide residues in...

Marinol qualifies as orphan drug in AIDS. (Unimed)
March 4, 1991... Unimed, Inc. announced that it has received notification from the U.S. Food and Drug Administration (FDA) that Marinol (dronabinol), Unimed's antinausea pharmaceutical for cancer chemotherapy patients, qualifies for designation as an orphan...

New appointments announced for hypericin development. (James M. McCormick and Hershel Herzog appointed to help develop antiviral drug) (VIMRx Pharmaceuticals)
March 4, 1991... VIMRx Pharmaceuticals announced the appointment of James M. McCormick to its board of directors and the appointment of Hershel Herzog, Ph.D., to the new position of scientific director. McCormick was a founder and vice president of Adria...

Acquisition of I.V. Therapy Associates announced. (Roberts Pharmaceutical)
March 4, 1991... Roberts Pharmaceutical Corporation, Eatontown, New Jersey, announced that it has concluded an agreement to acquire I.V. Therapy Associates (IVT), a privately owned infusion therapy company based in Charleston, S.C. Roberts stated that the...

Mouse model exhibits human-like immune response to HIV infection. (LIDAK Pharmaceuticals and Medical Biology Institute)
March 4, 1991... LIDAK Pharmaceuticals and Medical Biology Institute (MBI) announced that a report published in Science shows for the first time that infection with HIV-1 leads to the same changes in immune function in a specific laboratory animal that occur...

Seth Rudnick named chief executive officer. (Cellular Transplants)
March 4, 1991... Cellular Transplants Inc., a developer of biotherapeutics for human health care, named Seth Rudnick, M.D., as chief executive officer. "I am excited by the prospect of contributing to the development of a major technology to provide new...

Groups sponsor youth video contest. (to encourage AIDS awareness) (American Cancer Society AIDS Task Force)
March 4, 1991... KCET Television, Los Angeles Community Outreach, the American Cancer Society AIDS Task Force, and other AIDS service organizations are conducting a High School AIDS Education Video Contest to encourage AIDS awareness among teenagers. ...

Chronic myelogenous leukemia as a model of abnormal growth and differentiation. (Research Report)
March 4, 1991... AUTHORS: Owen N. Witte. University of California at Los Angeles. According to the author's abstract of a presentation to the 43rd annual Symposium on Fundamental Cancer Research, held in Houston, "The structural events that activate the...

Functional platelet-derived growth factor (PDGF)-beta receptors on rat neuronal cells in culture suggest a neurotrophic activity of PDGF. (Research Report)
March 4, 1991... AUTHORS: Anja Smits, Bengt Westermark, Monica Nister, Carl-Henrik Heldin and Keiko Funa. Ludwig Institute for Cancer Research, Uppsala, Sweden. According to the author's abstract of a presentation to the 43rd annual Symposium on...

Quantitative analysis of epidermal growth factor receptor binding and trafficking: modelling insights into the role of EGF receptor tyrosine kinase activity. (Research Report)
March 4, 1991... AUTHORS: Cindy Starbuck, H. Steven Wiley and Douglas A. Lauffenburger. University of Pennsylvania at Philadelphia and University of Illinois at Urbana. According to the author's abstract of a presentation to the 43rd annual Symposium...

Transactivation of pancreas-specific genes in somatic cell hybrids. (Research Report)
March 4, 1991... AUTHORS: K.J. Wu, L.C. Samuelson, G. Howard, M.H. Meisler and G.J. Darlington. Baylor College of Medicine, Houston, Texas, and University of Michigan Medical School at Ann Arbor. According to the author's abstract of a presentation to...

Treatment of hematologic malignancies with biologic growth regulators. (Research Report)
March 4, 1991... AUTHORS: Jordan U. Gutterman, Moshe Talpaz, Razelle Kurzrock and Saroj Vadhan. M.D. Anderson Cancer Center, Houston, Texas. According to the authors' abstract of a presentation to the 43rd annual Symposium on Fundamental Cancer...

Prognostic factors in aggressive malignant lymphomas; description and validation of a prognostic index that could identify patients requiring a more intensive therapy. (Periodical Report)
March 4, 1991... SOURCE: Journal of Clinical Oncology, February, 1991;9(2):211-219.] A prognostic index including increased lactic dehydrogenase (LDH) levels, tumor stage, number of extranodal sites, and tumor mass may help distinguish between malignant...

Prognosis of pregnancy-associated breast cancer. (Periodical Report)
March 4, 1991... SOURCE: Cancer, February 15, 1991;67(4):869-872. A Memorial Sloan-Kettering Cancer Center report suggests that women with pregnancy-associated (PA) breast cancer are no more likely to die of the disease than other breast cancer patients....

Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada. (Periodical Report)
March 4, 1991... SOURCE: International Journal of Cancer, February, 1991;47:323-328. A University of Toronto study offers further evidence of a causal relationship between cigarette smoking and cancer of the pancreas. A number of epidemiologic...

Ifosfamide continuous infusion without Mesna: a phase I trial of a 14-day cycle. (thiol scavenger not needed to control toxic effects of chemotherapeutic agent) (Periodical Report)
March 4, 1991... SOURCE: Cancer, February 15, 1991;67(4):883-885. A protracted infusion schedule for the chemotherapeutic agent ifosfamide permits outpatient treatment without the addition of Mesna to limit bladder toxicity, according to a Cancer Center...

Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. (Periodical Report)
March 4, 1991... SOURCE: Journal of Clinical Oncology, February, 1991;9(2):204-210. Combination chemotherapy with intraperitoneal cisplatin and cytarabine appears to be effective in patients with minimal residual ovarian cancer, but not in those with...

Studies with RP 56976 (taxotere): a semisynthetic analog of taxol. (antimitotic agent potent against cancer cells) (Periodical Report)
March 4, 1991... SOURCE: Journal of the National Cancer Institute, February 20, 1991;83(4):289-291. The taxol analog taxotere appears to be a potent antimitotic agent in both taxol-responsive and -resistant cells, according to an Israeli report. ...

Aspirin may decrease colorectal cancer risk. (U.S. National Cancer Institute)
March 11, 1991... DATELINE: U.S. NCI The regular use of aspirin may reduce the risk of colorectal cancer by as much as half, according to the results of a multicenter study conducted in the northeastern United States. Nonsteroidal antiinflammatory...

Value of prostate screening unclear. (cancer) (University of Chicago)
March 11, 1991... DATELINE: University of Chicago The value of prostate cancer screening remains unclear, insist two researchers from the University of Chicago Medical Center reporting in the March 6, 1991, issue of the Journal of the National Cancer...

Fat intake linked to breast cancer. (National Cancer Institute of Canada)
March 11, 1991... DATELINE: National Cancer Institute of Canada A Canadian study lends evidence to the belief that consumption of dietary fat is a risk factor for breast cancer. For some time cancer researchers have speculated that fat intake...

Breast cancer chemotherapy may increase risk for esophagus cancer. (Italy)
March 11, 1991... DATELINE: Italy Italian researchers, reporting in Annals of Internal Medicine, say chemotherapy commonly given breast cancer patients may increase the risk for cancer of the esophagus. Six months of treatment with the drugs...

Cytogen reports favorable results in cancer imaging and therapy. (International Conference on Monoclonal Antibody Immunoconjugates)
March 11, 1991... Advances in the use of monoclonal antibodies to image and treat cancer were reported by Cytogen Corporation and its collaborators at the Sixth International Conference on Monoclonal Antibody Immunoconjugates in San Diego, California. ...

Quadra Logic Technologies Inc.'s BPD attached to monoclonal antibodies. (photosensitizer Benzoporphyrin Derivative) (Fifth Symposium on Recent Advances in Drug Delivery Systems)
March 11, 1991... Quadra Logic Technologies Inc. (QLT) reported that the company has developed technology to attach its proprietary photosensitizer Benzoporphyrin Derivative (BPD) to monoclonal antibodies. The combined delivery system developed and patented by...

New process to synthesize pharmaceutical compounds for cancer. (Harrier, Inc.)
March 11, 1991... Harrier, Inc., Durham, North Carolina, announced that the synthetic process and chemical structure of its anticancer compound have been confirmed by research scientists at a U.S. university. According to the company, the detailed chemical...

Oral alpha-interferon announcement. (trial planned) (Hoffmann-La Roche and Cortecs Limited)
March 11, 1991... Cortecs Limited, London, issued the following statement regarding a joint oral alpha-interferon study with Hoffmann-La Roche: "Following initial positive results from a joint study at the Macromolecular Clinical Research Centre in Korea,...

Group announces unparalleled achievement in U.S. sales in 1990. (ICI Pharmaceuticals)
March 11, 1991... ICI Pharmaceuticals Group announced its 1990 U.S. sales exceeded $1.1 billion. The achievement establishes ICI Pharmaceuticals Group as the top business unit of ICI Americas Inc. in gross sales. "Achieving more than $1 billion in annual...

Warning of raw milk hazards. (bacterial contamination) (California Medical Association)
March 11, 1991... Raw certified milk not only provides no measurable health benefits, but actually poses significant health hazards because of bacterial contamination risks, the California Medical Association (CMA) declared in a recently filed legal brief. ...

Medical research bill gains house approval; seen as stimulus to medical school ventures. (funds for medical research) (U.S. House of Representatives)
March 11, 1991... The U.S. House of Representatives gave its okay to a measure which would provide matching federal funds for the creation of new medical research centers. The legislation would authorize a coalition of medical schools and military and...

Preferred vendor agreement signed with HemoCare, Inc. (Health Systems Group)
March 11, 1991... Health Systems Group, a unit of American Express Information Services Corporation, announced that it has entered into a preferred vendor arrangement with HemoCare, Inc. of Melville, N.Y. Under the terms of the agreement, Health Systems...

Radar health study. (microwave energy emissions from police traffic radar's antenna) (Ohio State Patrol)
March 11, 1991... The Ohio State Highway Patrol released the results of its study on the safety of police traffic radar. The study was initiated last year in response to allegations that microwave energy emissions from the radar's antenna produced hazardous...

New product priorities unveiled. (pharmaceuticals' product development plans) (Marion Merrell Dow)
March 11, 1991... Marion Merrell Dow Inc. reviewed new-product development plans that will move the company into additional therapeutic areas and increase the company's presence in prescription and over-the-counter (OTC) categories where it already has...

SBIR grant awarded to develop antisense therapeutics. (Small Business Innovation Research from National Institutes of Health) (MicroProbe)
March 11, 1991... MicroProbe Corporation, Bothell, Washington, a privately held biomedical company, said it was awarded a $50,000 Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. The grant will be used to study...

A critical assessment of trials of neoadjuvant (preemptive) chemotherapy for bladder cancer: lesson for future studies of combined modality treatment. (Research Report)
March 11, 1991... AUTHORS: Derek Raghavan. Royal Prince Alfred Hospital, Sydney, Australia. According to the author's abstract of a presentation to the Third International Conference on the Interaction of Radiation Therapy and Systemic Therapy, held in...

Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of randomized trial. (Research Report)
March 11, 1991... AUTHORS: Jean-Marc Bachaud, Jean-Marc David, Gerard Boussin and Nicolas Daly. Center Claudius Regaud, Toulouse, France. According to the authors' abstract of a presentation to the Third International Conference on the Interaction of...

Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. (Research Report)
March 11, 1991... AUTHORS: Philip Bonomi, Meryl Gale, Kendrith Rowland, Samuel G. Taylor, Sandra Purl, Salitha Reddy, Mai S. Lee, Alexander Phillips, C. Frederick Kettle, William Warren and Penfield Faber. Carle Clinic, Champaign, Ill. According to the...

Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors. (Research Report)
March 11, 1991... AUTHORS: Sara Rockwell, Christine S. Hughes and Katherine A. Kennedy. Yale University School of Medicine, New Haven, Connecticut, and George Washington University Medical Center, Washington, D.C. According to the authors' abstract of a...

Radiosensitizing and cytotoxic properties of Mitomycin C in a C3H mouse mammary carcinoma in vivo. (drug) (Research Report)
March 11, 1991... AUTHORS: Cai Grau and Jens Overgaard. Danish Cancer Society, Denmark. According to the authors' abstract of a presentation to the Third International Conference on the Interaction of Radiation Therapy and Systemic Therapy, held in...

Inhibition of recovery from potentially lethal radiation damage in A549 cells by the K+/H+ ionophore nigericin. (Research Report)
March 11, 1991... AUTHORS: Marie E. Varnes, Harry J. Menegay and David S. McKenna. Case Western University, Cleveland, Ohio. According to the authors' abstract of a presentation to the Third International Conference on the Interaction of Radiation Therapy...

Proliferation and DNA ploidy in malignant breast tumors in relation to early contraceptive use and early abortions. (oral contraceptives) (Periodical Report)
March 11, 1991... SOURCE: Cancer, March 1, 1991;67(5):1285-1290. Early oral contraceptive use appears to be a significant predictor of poor prognosis in breast cancer, according to a Swedish study. For decades cancer researchers have attempted to...

Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. (Periodical Report)
March 11, 1991... SOURCE: Journal of the National Cancer Institute, March 6, 1991;83(5):341-346. Genetic analysis appears to be a valuable tool in diagnosing certain poorly differentiated cancers of uncertain histology, according to a New York study. ...

Fludarabine therapy in hairy cell leukemia. (Periodical Report)
March 11, 1991... SOURCE: Cancer, March 1, 1991;57(5):1291-1293. An M.D. Anderson Cancer Center study offers the first clinical evidence that the adenine nucleoside analog fludarabine has efficacy in the treatment of hairy cell leukemia. Although...

Obesity and colorectal adenomatous polyps. (Periodical Report)
March 11, 1991... SOURCE: Journal of the National Cancer Institute, March 6, 1991;83(5):359-361. A New York study suggests that obese women have more adenomatous polyps than women of normal weight, but the association was not seen in men. ...

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection. (antitumor drug etanidazol) (Periodical Report)
March 11, 1991... SOURCE: Cancer Research, February 15, 1991;51:1099-1104. The misonidazole analog etanidazol (SR-2508) showed some chemosensitization properties in a group of advanced cancer patients when given with cyclophosphamide. Preclinical...

New drug, GM-CSF, approved for cancer patients. (granulocyte macrophage colony stimulating factor to accelerate the growth of transplanted bone marrow) (U.S. Food and Drug Administration)
March 18, 1991... DATELINE: U.S. FDA The U.S. Food and Drug Administration (FDA) approved a biotech product that speeds the recovery of cancer patients by accelerating the growth of bone marrow transplanted as part of their treatment. The product is...

$4.6 million federal jury award to New York woman after breast implant found to have caused cancer. (New York City)
March 18, 1991... DATELINE: New York City Denise M. Dunleavy, lawyer for the 46-year-old New York woman awarded $4.6-million by a federal jury, said the award marked the first time that a federal court has ever linked a breast implant to cancer. The...

Fludarabine shows promise in treatment of CLL. (chronic lymphocytic leukemia) (M.D. Anderson Cancer Center)
March 18, 1991... DATELINE: M.D. Anderson Cancer Center The investigational cytoreductive agent fludarabine phosphate appears to offer superior treatment for relapsed or refractory chronic lymphocytic leukemia (CLL), according to four M.D. Anderson Cancer...

Arthur D. Little receives contract to study potential cancer preventive foods. (Arthur D. Little's Center for Technology and Product Development) (U.S. National Cancer Institute)
March 18, 1991... DATELINE: U.S. NCI Arthur D. Little's Center for Technology and Product Development has been awarded a $6.3 million contract by The Diet and Cancer Branch of the U.S. National Cancer Institute (NCI) to provide technical support for the...

Collaboration to develop new generation cancer drugs. (Sandoz Pharmaceuticals Ltd. and Dana-Farber Cancer Institute)
March 18, 1991... DATELINE: Sandoz and Dana-Farber Cancer Institute Sandoz Pharmaceuticals Ltd., its affiliate Sandoz Pharmaceuticals Corporation and Dana-Farber Cancer Institute, Inc. announced a long-term collaboration to discover and develop a new...

Biomerica Inc. plans new test for gastritis and peptic ulcers. (enzyme immunoassay to test for Helicobacter pylori bacteria) (U.S. Food and Drug Administration)
March 18, 1991... DATELINE: U.S. FDA Biomerica Inc. announced that it has applied for FDA clearance to market an enzyme immunoassay for antibodies to Helicobacter pylori, a bacterium that has been linked to duodenal ulcers and other gastric ailments. The...

New treatment for leading viral STD. (Condylox, a topical solution for external genital warts, a sexually transmitted disease) (Oclassen Pharmaceuticals Inc. and Burroughs Wellcome Co.)
March 18, 1991... Oclassen Pharmaceuticals announced that it has signed a major co-promotion agreement with Burroughs Wellcome Co. for Oclassen's flagship product, Condylox (podofilox) 0.5 percent topical solution. Condylox received approval by the U.S....

Ciliary Neurotrophic Factor patent awarded. (No. 4,997,929, for treatment of peripheral neuropathies) (Synergen)
March 18, 1991... Synergen Inc. announced that it has obtained U.S. Patent 4,997,929 for DNA sequences and methods of making Ciliary Neurotrophic Factor (CNTF). Synergen is developing CNTF, a human protein, as a treatment for peripheral neuropathies as part of...

Interferon license agreement expanded. (under Patent No. 4,503,035 for anticancer drug) (Hoffmann-La Roche and Interferon Sciences)
March 18, 1991... Hoffmann-La Roche Inc. and Interferon Sciences, Inc., an 82 percent-controlled subsidiary of National Patent Development Corporation, announced they had reached agreement on a broadened license under Hoffmann-La Roche's U.S. Patent No....

Millions of lives, billions in health care costs to be saved by pharmaceutical R&D, study shows. ("The Value of Pharmaceuticals: An Assessment of Future Costs for Selected Conditions" report on effect of research and development on health care costs) (Battelle Medical Technology Assessment and Policy Research Center)
March 18, 1991... Millions of lives and billions of dollars will be saved in the next 25 years, thanks to advances made possible by pharmaceutical research. In fact, investments in new drug development can be viewed as a vital part of the solution to cut...

1990 results of operations. (U.S. Bioscience)
March 18, 1991... U.S. Bioscience Inc. reported revenues of $1,407,295 and a net loss of $1,281,411, or 8 cents per share, for its fourth quarter ended December 31, 1990. Revenues for the full year 1990 were $3,452,639 and the net loss was $4,924,849, or...

Smokeless tobacco banned in four minor leagues. (National Association of Professional Baseball Leagues)
March 18, 1991... The use of smokeless tobacco will be forbidden this season at all ball parks in four rookie and short-season A leagues of the National Association, Baseball Commissioner Francis T. Vincent, Jr. announced in Dallas. The ban will be...

$4 million private sale of stock. (Immunomedics)
March 18, 1991... Immunomedics, Inc. announced the completion of a $4 million private placement of non-dividend paying Series A convertible preferred stock. Proceeds from the offering will be used to fund the company's clinical programs and general...

Amalgam restorations pose no harm to human immune system. (from mercury in dental amalgams) (American Dental Association)
March 18, 1991... Amalgam restorations have no adverse effects on the human immune system, nor does mercury from amalgam result in "reduced immunocompetence" or a diminished function of the system, according to a study published in the March Journal of the...

Residents fear cancer more than heart disease. (Philadelphia)
March 18, 1991... Philadelphia residents feel very much in control of their cardiovascular destiny and fear cancer more than they do heart disease. The poll of 250 Philadelphians over 30 years of age was supported by an educational grant from the Kansas...

Julia O. Barnes named director. (Planned Parenthood Southeastern Pennsylvania)
March 18, 1991... Julia O. Barnes, former commanding officer of the U.S. Naval Hospital, Great Lakes, Ill., has been appointed executive director of Planned Parenthood Southeastern Pennsylvania (PPSP). Barnes will oversee the agency's programs, which...

Episomal amplification of epidermal growth factor receptor in a colorectal cancer cell line. (Research Report)
March 18, 1991... AUTHORS: Roger R. Hewitt, Maureen Goode, Debbie Brock, Norman Prather, Randy Legerski and Michael Siciliano. University of Texas M.D. Anderson Cancer Center at Houston. According to the authors' abstract of a presentation to the...

Effect of high-dose transforming growth factor alpha (TGF-alpha) on the growth of human breast cancer: comparison with TGF-beta. (Research Report)
March 18, 1991... AUTHORS: Yufeng Lu and Yunxiang Wang. Harbin Medical University, Harbin, China. According to the authors' abstract of a presentation to the Forty-Third Annual Symposium on Fundamental Cancer Research, held in Houston, "The purpose of...

Protein kinase associated with the herpes simplex virus type 2 transforming protein ICP-10 has properties similar to growth factor receptor kinases. (Research Report)
March 18, 1991... AUTHORS: Cynthia Smith, Theodore Chung, James P. Wymer, Patrizia Terzano and Laure Aurelian. University of Maryland School of Medicine at Baltimore and University of Bologna, Bologna, Italy. According to the author's abstract of a...

Colony stimulating factor-1 receptor-mediated signal transduction in macrophages declines with age. (Research Report)
March 18, 1991... AUTHORS: Victor L. Sylvia, Goutam Ghosh Choudhury, Gabriel Fernandes, Bong K. Lee and Alan Y. Sakaguchi. The University of Texas M.D. Anderson Cancer Center. According to the authors' abstract of a presentation to the Forty-Third...

Induction of interleukin-6 mRNA in Epstein-Barr virus-immortalized human B cells. (messenger RNA) (Research Report)
March 18, 1991... AUTHORS: A. Wodnar-Filipowicz, A. Tichelli, M. Fey and C. Nissen. Institute of Medical Oncology, Inselspital Bern, Switzerland. According to the authors' abstract of a presentation to the Forty-Third Annual Symposium on Fundamental...

Autonomous growth of factor dependent mouse myeloid leukemia after retroviral human granulocyte colony-stimulating factor infection. (Research Report)
March 18, 1991... AUTHORS: Junichiro Fujimoto, Nobutaka Kiyokawa and Yasuo Kokai. National Children's Medical Research Center, Tokyo, Japan. According to the authors' abstract of a presentation to the Forty-Third Annual Symposium on Fundamental Cancer...

The Lewis X antigen: an new paraffin section marker for Reed-Sternberg cells. (Periodical Report)
March 18, 1991... SOURCE: Cancer, March 1, 1991;67(5):1338-1346. Lewis X antigen staining appears to be a useful marker for Reed-Sternberg (R-S) cells and is superior to Leu-M1, according to a New York study. R-S cells carry natural ligands of...

Expression of cathepsin L in human tumors. (Periodical Report)
March 18, 1991... SOURCE: Cancer Research, March 1, 1991;51:1478-1481. The lysosomal cysteine protease cathepsin L may prove to be a useful diagnostic or prognostic tool in cancer patients, according to a U.S. National Cancer Institute report. ...

Phase II study of aminothiadiazole in advanced squamous cell carcinoma of the esophagus. (anticancer agent) (Periodical Report)
March 18, 1991... SOURCE: American Journal of Clinical Oncology, February, 1991;14(1):33-35. An Eastern Cooperative Oncology Group study suggests that the experimental agent aminothiadiazole (A-TD) has no activity in the treatment of advanced squamous...

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. (drug) (Periodical Report)
March 18, 1991... SOURCE: Journal of Clinical Oncology, March, 1991;9(3):491-498. The deoxycytidine analog gemcitabine has a maximum-tolerated dosage of 790 mg/m2 per week, and should be given at this dosage in future phase II testing, according to an...